Cellestis is a unique global investment which is on the brink of generating substantial profits from its revolutionary Tuberculosis (TB) diagnostic, Quantiferon TB Gold (QFTG). The Company has a massive market, high profit margin and a global monopoly with patent protection to 2017 and possibly 2021, on the world’s leading killer infectious disease. And it has tremendous “blue sky” potential for other new diagnostics.
Massive Market
The World Health Organisation (WHO) estimates that a staggering one-third of the world’s population is infected with latent TB infection and has declared TB a global health emergency – the only disease for which this has been done. TB is responsible for nine million new cases and more than two million deaths annually. The spread of Multi-Drug Resistant TB has health authorities even more alarmed. The biggest obstacle to TB control has been the lack of an adequate TB diagnostic. QFTG is a new TB blood test, which the world’s leading TB authorities are hailing as a “paradigm shift” with “profound” public health implications, that will “revolutionize” how TB is diagnosed.
FDA Approval
QFTG has been subject to a multitude of independent studies by researchers from around the world. The US Food & Drug Administration (FDA) approved QFTG in December 2004 and the US Centers for Disease Control (CDC) in December 2005.
CST Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
